The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice

Diabetes

Volumn 47, Issue 4, 1998, Pages 570-575

  Liang, Lijin ^a   Beshay, Evette ^a   Prud'homme, Gérald J ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b Department of Pathology ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; INSULITIS; INTRAPERITONEAL DRUG ADMINISTRATION; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; CYCLOPHOSPHAMIDE; DIABETES MELLITUS, TYPE 1; FEMALE; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-4; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; PANCREAS; PENTOXIFYLLINE; PERITONEAL CAVITY; PHOSPHODIESTERASE INHIBITORS; PYRROLIDINONES; ROLIPRAM; SPLEEN; SUPERANTIGENS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031921308     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.47.4.570     Document Type: Article

References (37)

1. Serreze DV, Leiter EH: Genetic and pathogenic basis of autoimmune diabetes in NOD mice. Curr Opin Immunol 6:900-906, 1994
2. Rothe H, Faust A, Schade U, Kleeman R, Bosse G, Hibito T, Martin S, Kalb H: Cyclophosphamide treatment of female non-obese diabetic mice causes enhanced expression of inducible nitric oxide synthase and interferongamma, but not interleukin-4. Diabetologia 37:1154-1158, 1994
3. Rabinovitch A, Suarez-Pinzon WR, Sorensen O, Bleackley RC, Power RF: IFN-gamma expression in pancreatic islet-infiltrating mononuclear cells correlates with autoimmune diabetes in non-obese diabetic mice. J Immunol 154:4874-4882, 1995
4. Rabinovitch A, Suarez WR, Thomas PD, Strynadka K, Simpson I: Cytotoxic effects of cytokines on rat islets: evidence for involvement of free radicals and lipid peroxidation. Diabetologia 35:409-413, 1992
5. Rabinovitch A, Suarez-Pinzon WL, Sorensen O: Interleukin-12 mRNA expression in islets correlates with beta-cell destruction in NOD mice. J Autoimmun 9:645-651, 1996
6. Tremblau S, Penna G, Bosi E, Mortara A, Gately MK, Adorini L: Interleukin-12 administration induces T-helper type 1 cells and accelerates autoimmune diabetes in NOD mice. J Exp Med 181:817-821, 1995
7. Campbell IL, Kay TW, Oxbrow L, Harrison, LC: Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NODAVEHI mice. J Clin Invest 87:739-742, 1991
8. Mahon JL, Dupre J, Stiller CR: Lessons learned from the use of cyclosporine for insulin-dependent diabetes mellitus. Annals NY Acad Sci 696:351-363, 1993
9. Campbell RK: Clinical update on pentoxifylline therapy for diabetes-induced peripheral vascular disease. Annals Pharmacother 27:1099-1105, 1993
10. Sonkin PL, Kelly LW, Sinclair SH, Hatchell DL: Pentoxifylline increases retinal capillary blood flow velocity in patients with diabetes. Arch Ophthalmol 111:1647-1652, 1993
11. Scott AI, Perini AF, Shering PA, Whalley LJ: In-patient major depression: is rolipram as effective as amitriptyline? Eur J Clin Pharmacol 40:127-129, 1991
12. Bobon D, Breulet M, Gerard-Vendenhove MA, Guiot-Goffioul F, Plomteux G, Sastre-Y-Hernandez M, Scratzer M, Troisfontaines B, von Frenckell R, Wachtel H: Is phosphodiesterase inhibition a new mechanism of antidepressant action? Eur Arch Psychiatry Neurol Sci 238:2-6, 1988
13. Rott O, Cash E, Fleischer B: Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T-helper 1- but not 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur J Immunol 23:1745-1751, 1993
14. Sommer N, Loschmann P-A, Northoff GH, Weller M, Steinbrecker A, Steinbach JP, Lichtenfels R, Meyermann R, Rietmuller A, Fontana A: The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Med 1:244-248, 1995
15. Badger AM, Olivera DL, Esser KM: Beneficial effects of the phosphodiesterase inhibitors BRL 61063, Pentoxifylline, and Rolipram in murine models of endotoxin shock. Circ Shock 44:188-195, 1994
16. Novak TJ, Rothenberg EV: cAMP inhibits induction of interleukin-2 but not of interleukin-4 in T-cells. Proc Natl Acad Sci USA 87:9353-9357, 1990
17. Charlton B, Bacey A, Slattery RM, Mandel TE: Cyclophosphamide-induced diabetes in NOD/WEHI mice. Diabetes 38:441-147, 1989
18. Prud'homme GJ, Fuks A, Colle E, Seemayer TA, Guttmann RD: Immune dysfunction in diabetes-prone BB rats. J Exp Med 159:463-476, 1984
19. Sekut L, Yarnall D, Stimpson SA, Noel LS, Bateman-Fite R, Clark RL: Anti-inflammatory activity of phosphodiesterase (PDE)-FV inhibitors in acute and chronic models of inflammation. Clin Exp Immunol 100:126-132, 1995
20. Schwarz A, Krone C, Trautinger F, Aragane Y, Neuner P, Luger TA, Schwarz T: Pentoxifylline suppresses irritant and contact hypersensitivity reactions. J Invest Dermatol 101:549-552, 1993
21. Hecht M, Muller M, Lohmann-Matthes M-L, Emmendorffer A: In vitro and in vivo effects of pentoxifylline on macrophages and lymphocytes derived from autoimmune MRL-lpr/lpr mice. J Leukoc Biol 57:242-249, 1995
22. Schudt C, Tenor H, Hatzelmann A: PDE isoenzymes as targets for anti-asthma drugs. Eur Respir J 8:1179-1183, 1995
23. + T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol 118:1945-1958, 1996
24. Semnler T, Gebert U, Eisenhut T, Moeller J, Schonharting NM, Allera A: Xan-thine derivatives: comparison between suppression of tumor necrosis factor-α and inhibition of cAMP phosphodiesterase activity. Immunol 78:520-525, 1993
25. + mice: defective regulation of cytokine receptors and protein kinase C. Proc Natl Acad Sci USA 90:9625-9629, 1993
26. Sriskandan S, Evans TJ, Cohen J: Bacterial superantigen-induced human lymphocyte responses are nitric oxide dependent and mediated by IL-12 and IFN-gamma. J Immunol 156:2430-2435, 1996
27. Rothe H, O'Hara RM Jr, Martin S, Kobb H: Suppression of cyclophosphamide-induced diabetes development and pancreatic Th1 reactivity in NOD mice treated with the interleukin (IL)-12 antagonist IL-12 (p40)2. Diabetologia 40:641-646, 1997
28. Raju PI, Tolman KC, Davis PJ, Ludden TM, Roy TK, Johnson FE: Distribution and metabolism of pentoxifylline in non-tumour-bearing mice. J Med 24:353-367, 1993
29. Parker JC, Van Volkenburg MA, Ketchum RJ, Brayman KL, Andrews KM: Cyclic AMP phosphodiesterases of human and rat islets of Langerhans: contributions of types III and IV to the modulation of insulin secretion. Biochem Biophys Res Commun 217:916-923, 1995
30. Netea MG, Blok WL, Kullberg B-J, Bemelmans M, Vogels M-T, Buurman WA, Van der Meer JW: Pharmacologic inhibitors of TNF production exert differential effects in lethal endotoxemia and in infection with live microorganisms in mice. J Infect Dis 171:393-399, 1995
31. Arias-Diaz J, Vara E, Torres-Melero J, Rodriguez JM, Balibrea JL: Pentoxifylline partially reverts the effect of tumor necrosis factor on human islets. Transplant Proc 26:698-700, 1994
32. Sengupta TK, Schmitt EM, Ivashldv LB: Inhibition of cytokines and JAK-STAT activation by distinct signalling pathways. Proc Natl Acad Sci USA 93:9499-9504, 1996
33. Ivashkiv LB, Schmitt EM, Castro A: Inhibition of transcription factor STAT1 in mononuclear cell cultures and T-cells by the cyclic AMP signalling pathway. J Immunol 157:1415-1421, 1996
34. Prud'homme GJ, Kono DH, Theofilopoulos AN: Quantitative PCR analysis reveals marked overexpression of IL-1-beta, IL-10, and interferon-gamma mRNA in the lymph nodes of lupus-prone mice. Mol Immunol 32:495-503, 1995
35. Rabinovitch A, Sumoski WL Theophylline protects against diabetes in BB rats and potentiates cyclosporin protection. Diabetologia 33:506-508, 1990
36. MacDonald MJ, Shahidi NT, Allen DB, Lustig RH, Mitchell TL, Comwell ST: Pentoxifylline in the treatment of children with new-onset 1 diabetes mellitus. JAMA 271:27-28, 1994
37. Dezube BJ, Lederman MM, Spritzler JG, Chapman B, Kowick JA, Flexner C, Dandos S, Mattiacci MR, Ahlers CM, Zhang L: High dose pentoxifylline in patients with AIDS: inhibition of tumour necrosis factor production. J Infect Dis 171:1628-1632, 1995